...
机译:HLA Ligandomics将组蛋白脱乙酰酶1鉴定为卵巢癌免疫疗法的靶标
Univ Tubingen Inst Cell Biol Dept Immunol Tubingen Germany;
Univ Tubingen Hosp Inst Pathol Tubingen Germany;
Univ Tubingen Inst Cell Biol Dept Immunol Tubingen Germany;
Univ Tubingen Hosp Dept Obstet &
Gynecol Tubingen Germany;
Univ Tubingen Hosp Dept Obstet &
Gynecol Tubingen Germany;
Univ Tubingen Inst Cell Biol Dept Immunol Tubingen Germany;
Univ Tubingen Hosp Dept Clin &
Expt Transfus Med Tubingen Germany;
Univ Tubingen Hosp Dept Obstet &
Gynecol Tubingen Germany;
Univ Tubingen Inst Cell Biol Dept Immunol Tubingen Germany;
Univ Tubingen Inst Cell Biol Dept Immunol Tubingen Germany;
Univ Tubingen Hosp Inst Pathol Tubingen Germany;
Univ Tubingen Hosp Inst Pathol Tubingen Germany;
Histone deacetylase; HLA; immunotherapy; ovarian cancer; peptide vaccination;
机译:HLA Ligandomics将组蛋白脱乙酰酶1鉴定为卵巢癌免疫疗法的靶标
机译:综合 - 奥米尔科和HLA-ligandomics分析,以鉴定CCRCC免疫疗法的新药靶标
机译:组蛋白脱乙酰基酶抑制剂,apididin通过II类组蛋白脱乙酰基酶4沉默抑制人卵巢癌细胞的迁移
机译:组蛋白脱乙酰酶:癌症治疗的表观遗传靶标
机译:组蛋白脱乙酰基酶抑制剂和钙蛋白酶抑制剂的抗卵巢癌作用。
机译:HLA配体组学确定组蛋白脱乙酰基酶1为卵巢癌免疫治疗的靶标
机译:HLA配体组学确定组蛋白脱乙酰基酶1为卵巢癌免疫治疗的靶标
机译:通过紫檀芪与组蛋白去乙酰化酶抑制剂组合靶向mTa1 / HIF-1α信号减弱前列腺癌进展(开放存取)。